来源：市场资讯 成份股方面，以岭药业表现最为强劲，涨幅高达9.7%，接近涨停；达仁堂和华润三九紧随其后，涨幅 分别为5.12%和4.12%。另一方面，三生国健、泽璟制药和通化金马表现较弱，跌幅分别为4.61%、 2.61%和2.41%。 （来源：医疗ETF） 11月7日，截至11时29分，药ETF（562050）盘中表现平稳，场内价格现涨0.0%，成交额为926.09万 元，基金最新规模为1.07亿元。 风险提示：以上产品由基金管理人发行与管理，代销机构不承担产品的投资、兑付和风险管理责任。投 资人应当认真阅读《基金合同》、《招募说明书》、《基金产品资料概要》等基金法律文件，了解基金 的风险收益特征，选择与自身风险承受能力相适应的产品。基金过往业绩并不预示其未来表现，基金投 资须谨慎！销售机构（包括基金管理人直销机构和其他销售机构）根据相关法律法规对本基金进行风险 评价，投资者应及时关注基金管理人出具的适当性意见，各销售机构关于适当性的意见不必然一致，且 基金销售机构所出具的基金产品风险等级评价结果不得低于基金管理人作出的风险等级评价结果。基金 合同中关于基金风险收益特征与基金风险等级因考虑因素不同而存在差异 ...

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 董事長 陳玉卿 中國，上海 2025 年1 1 月6 日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 為控股子公司提供擔保的進展公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 ...

证券代码：600196 证券简称：复星医药 公告编号：临 2025-173 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | 名称 | 复星医药产业 | | --- | --- | --- | | | 本次担保金额 | 人民币 20,000 万元 | | 被担保方 1 | 截至 2025 年 11 月 6 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 折合人民币 919,116 万元 | | | 是否在前期预计额度内 | 是 □否 □不适用：________ | | | 本次担保是否有反担保 | 被担保方 1 系担保方（本公司）之全 资子公司，不涉及反担保安排 | | 被担保方 | 名称 | 复星安特金 | | | 本次担保金额 | 人民币 30,000 万元 | | 2 | 截至 2025 年 11 月 6 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 人民币 137,607 万元 | | | 是否在 ...

Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, showcasing innovations in the medical device and pharmaceutical sectors under the theme "Healthy China, Beautiful Life" [1] - The medical device and pharmaceutical health exhibition area, known for its high competition, featured global leaders in medical technology and pharmaceuticals, including the top ten medical device companies and 11 Fortune 500 pharmaceutical firms [1] Company Highlights - **Roche**: Displayed over 40 products, including new treatments for Alzheimer's, Parkinson's, and lupus nephritis, with the anti-CD20 monoclonal antibody, Gazyva, and the Port Delivery System (PDS) for eye diseases being key highlights [2][4][5] - **Siemens**: Focused on high-incidence cancers, showcasing advanced technologies like the ARTIS icono ceiling Xpand and the Biograph Vision Quadra PET/CT, aimed at improving diagnostic precision and treatment outcomes [6][7] - **Novartis**: Presented nearly 20 innovative products, including the oral complement factor B inhibitor, Iptacopan, and the radioligand therapy drug, Pluvicto, which received approval for prostate cancer indications [10][12] - **Fosun Pharma**: Introduced the Marie upright particle therapy system, a revolutionary cancer treatment technology, along with advanced non-invasive treatment systems for neurological conditions [12][14] - **Boston Scientific**: Showcased over 80 products in the minimally invasive intervention field, including the Orbera365 gastric balloon system and the Intera3000 hepatic artery infusion pump, with several products making their debut [15][17] - **Novo Nordisk**: Highlighted advancements in diabetes and obesity treatments, including the oral GLP-1 receptor agonist, Rybelsus, and the weekly insulin formulation, IcoSema, which have significantly improved patient convenience [18][20]

（制表：上海上市公司协会） （注：上海证券交易所自2023年起发布科创板上市公司信息披露评价结果；北京证券交易所自2025年起 发布北京证券交易所上市公司信息披露评价结果。） 近期，沪深北交易所陆续公布了上市公司信息披露评价结果。根据《沪市上市公司2024至2025年度信息 披露工作评价结果》、《关于深市上市公司2024-2025年度信息披露工作评价结果的通报》、《关于发 布2024-2025年度北京证券交易所上市公司信息披露工作评价结果的公告》显示，上海辖区89家上市公 司信息披露评价结果获得A，其中沪市主板44家、深市主板4家、创业板12家，科创板25家，北交所4 家。据统计，共有44家上市公司连续三个年度获得信息披露考评结果A，17家上市公司连续五个年度获 得信息披露考评结果A。其中，复星医药（600196）连续五年获上交所信息披露A级评价。 详见下表： ...

Core Insights - The 8th China International Import Expo (CIIE) showcases innovative medical devices and pharmaceuticals from global giants like Novartis, Roche, Pfizer, Siemens Healthineers, and Philips, highlighting the latest advancements in medical technology [1] - Chinese domestic innovation is also significant, with companies like Fosun Pharma and Weisheng Pharma presenting leading-edge products and collaborations, indicating a robust local industry [1][2] - By the first half of 2025, the total amount of overseas licensing for Chinese innovative drugs is projected to reach $60 billion, accounting for 99% of global related transactions [1] Group 1: Innovative Products - Siemens Healthineers showcased a 1,000 square meter exhibit featuring a rapid spectral angiography system capable of detecting small tumors in 2.5 seconds [2] - Novartis presented 11 Galien Award-winning products, emphasizing its strong innovation track record with nearly 80 awards since 1970 [2] - Fosun Pharma displayed advanced products such as the Da Vinci surgical robot and CAR-T cell therapy, demonstrating its commitment to cutting-edge medical technology [2] Group 2: Local Innovation and Market Adaptation - Companies like Zhuhai Respira and Shenzhen Weide are developing innovative solutions tailored to the Chinese market, with rapid development cycles and efficient clinical research [3] - The trend of "localized innovation" is prevalent, with many foreign companies adapting their products to meet local needs, as seen with Carl Zeiss and Varian Medical Systems [4][6] - Philips has established five innovation centers and five manufacturing bases in China, with over 95% of its products developed and manufactured locally [6] Group 3: Foreign Investment and Market Engagement - Foreign companies are increasing investments in China, with plans for new facilities and projects, such as Novartis's radioactive drug production base expected to be operational by the end of 2026 [7] - Medtronic has set up a regional venture capital fund in China, investing in over 10 local medical technology startups to enhance innovation [7] - Companies are also targeting county and grassroots markets in China, with tailored products like fully automated biochemical analyzers designed for local healthcare environments [8]

Core Insights - The 8th China International Import Expo (CIIE) opened on November 5, 2023, in Shanghai, featuring participation from 155 countries and regions, with six countries serving as guest countries [1] - The exhibition area exceeded 430,000 square meters, with 4,108 participating companies, an increase of over 600 from the previous year, including 290 Fortune 500 and industry-leading companies, marking the highest participation to date [1] - CIIE has evolved beyond a mere international procurement platform to become a crucial link in the domestic and international dual circulation [1] Group 1: Company Participation - Schneider Electric, a "full attendance" participant, showcased its R&D achievements under the "China-centric" strategy, presenting new products developed in China [2] - Johnson Controls views CIIE as a strategic platform for its development in China, focusing on digitalization, clean energy, and advanced manufacturing [3] - Fosun Pharma has leveraged CIIE's spillover effects to accelerate the introduction of innovative medical technologies and products into the Chinese market [4][5] Group 2: Innovation and New Products - CIIE serves as a stage for global product launches, with 461 new products, technologies, and services showcased, turning China into a testing ground for global innovation [6] - Honeywell highlighted its 90-year history in China, presenting eight new products, many of which were developed locally [6] - Bayer emphasized CIIE as a strategic platform for integrating into China's economic development, showcasing 26 highlighted products, including five global debuts [7] Group 3: Market Impact - The cumulative intended transaction amount from the first seven CIIEs exceeded $500 billion, reflecting its growing influence and scale [8] - CIIE is a vivid representation of China's open stance towards the world, providing a broad platform for global companies to share opportunities and collaborate on development [8]

Core Insights - The eighth China International Import Expo (CIIE) showcased several innovative medical devices and healthcare products, attracting significant attention from global trade delegations [1][2] Group 1: Medical Devices - Boston Scientific presented the ENROUTE Transcarotid Artery Revascularization (TCAR) device, the first and only approved device for TCAR procedures, aimed at reducing intraoperative risks associated with carotid artery stenosis [1] - Another product from Boston Scientific, the FARAWAVE NAV catheter, utilizes non-thermal electric fields for cardiac tissue ablation and has treated approximately 500,000 patients globally [1] - Medtronic introduced the Inceptiv closed-loop rechargeable spinal nerve stimulation system, designed to improve the quality of life for patients with chronic pain through weak electrical stimulation [4] - BD Medical showcased the M.R.I™ 4F Slim Implantable Port, the thinnest catheter in its category, designed for the Chinese population, which significantly reduces thrombosis rates by 40% [4] - The Venclose™ catheter, designed for treating lower limb varicose veins, features a flexible setup that minimizes patient trauma [5] Group 2: Innovative Treatments - Fosun Pharma presented the Exablate Neuro system, a high-intensity focused ultrasound (HIFU) device combined with MRI for treating drug-resistant essential tremors and Parkinson's disease [6] - Eli Lilly introduced innovative drugs targeting aging and obesity, including donanemab for Alzheimer's disease, which has shown to delay disease progression by approximately 30% in clinical trials [6]

Core Insights - The China International Import Expo (CIIE) showcases innovative products across various sectors, including healthcare and automotive, with a record participation of 155 countries and over 4,108 foreign enterprises [1][2] Product Highlights - Notable medical products include the Ferghana needleless intravenous catheter, which reduces the risk of needle-stick injuries, and the 3DMax hernia repair patch, designed for quick deployment and reduced postoperative pain [2] - The Marie particle therapy system by Fosun Pharma represents a revolutionary advancement in cancer treatment, offering a cost-effective and space-saving alternative to traditional systems [2] - Tesla's Cybercab, an autonomous electric vehicle, features a streamlined design without a steering wheel or pedals, utilizing a vision processing system for self-driving capabilities [3] Market Entry and Transformation - The CIIE serves as a platform for global medical technology companies to convert exhibits into market-ready products, with BD Medical reporting that nearly 95% of their showcased products have entered the market [4] - Fosun Pharma has leveraged the CIIE to accelerate the introduction of cutting-edge technologies and innovative medical products into China [4] Investment Opportunities - The CIIE has attracted foreign exhibitors to become investors in China, with BD Medical planning to establish a new innovation center in Tianjin [5] - Tutti Pharmaceuticals, which successfully entered the Chinese market last year, is now considering building a factory in China to enhance its research and development capabilities [6]

Core Insights - The China International Import Expo (CIIE) showcases innovative products across various sectors, including healthcare and automotive, with a record participation of 155 countries and over 4,108 foreign enterprises [1][2] - The event serves as a platform for global companies to introduce their products to the Chinese market, facilitating the transformation of exhibits into commercial products [3][4] Healthcare Innovations - BD Medical introduced the Ferghana needle-free intravenous catheter and the 3DMax hernia repair patch, which enhance safety and efficiency in medical procedures [1] - Fosun Pharma presented the Marie upright particle therapy system, offering a cost-effective and space-saving alternative to traditional radiation therapy systems [2] Market Entry and Product Commercialization - BD Medical reported that nearly 95% of its showcased products have been commercialized, accelerating the entry of its products into Chinese hospitals [3] - The CIIE has enabled companies like Fosun Pharma to successfully launch advanced technologies and innovative medical products in China [3] Investment Opportunities - The CIIE has attracted exhibitors to become investors, with BD Medical planning to establish a new innovation center in Tianjin [4] - Companies like Tutti Pharma have successfully entered the Chinese market through the CIIE and are now considering local manufacturing due to favorable conditions [4]